Development of an intranasal, long duration opioid antagonist to treat opioid overdose
Ended Cooperative Agreement Awarded Last action
- Award ID
- U01DA046093
- Recipient
-
Opiant Pharmaceuticals, Inc. UEI KM23KYBML5N8
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $10,988,735
Award facts
- Assistance listing
- 93.279 Drug Use and Addiction Research Programs
- Completion date
- Originally
- Funding
-
- $9,188,154.00 Federal
- $1,800,581.00 Non-federal
- Place of performance
- Texas, USA
Award details come from USAspending.gov.
Transactions
| Action | Federal | Non-federal | Date |
|---|---|---|---|
| Amendment | $0 | $0 | |
| Amendment | $1,800,581 | $0 | |
| Amendment | $1,800,581 | $1,800,581 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $3,035,646 | $0 | |
| Amendment | $0 | $0 | |
| Original award | $2,551,346 | $0 |
Quick answers
Who received award U01DA046093?
U01DA046093 was awarded to Opiant Pharmaceuticals, Inc. by National Institute on Drug Abuse (National Institutes of Health) on May 1, 2018.
How much is award U01DA046093 worth?
$10,988,735 has been obligated on U01DA046093: $9,188,154 in federal funding and $1,800,581 in non-federal funding.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award